Nuvalent, Inc. (NUVL): Price and Financial Metrics
GET POWR RATINGS... FREE!
NUVL Stock Price Chart Interactive Chart >
NUVL Price/Volume Stats
| Current price | $9.44 | 52-week high | $40.82 |
| Prev. close | $9.17 | 52-week low | $7.09 |
| Day low | $8.89 | Volume | 106,800 |
| Day high | $9.67 | Avg. volume | 168,415 |
| 50-day MA | $10.98 | Dividend yield | N/A |
| 200-day MA | $19.06 | Market Cap | 456.08M |
Nuvalent, Inc. (NUVL) Company Bio
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Latest NUVL News From Around the Web
Below are the latest news stories about Nuvalent Inc that investors may wish to consider to help them evaluate NUVL as an investment opportunity.
Nuvalent Appoints Emily Drabant Conley, PhD, to Board of DirectorsNuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Emily Drabant Conley, Ph.D., Chief Executive Officer of Federation Bio, to its Board of Directors. |
Nuvalent begins dosing in phase 1/2 trial of NVL-520 for solid tumors, lung cancerNo summary available. |
Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective InhibitorNuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the first patient has been dosed in ARROS-1, its Phase 1/2 clinical trial evaluating NVL-520 in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other advanced solid tumors. NVL-520, Nuvalent's lead product candidate, is a novel ROS1-selective inhibitor designed to address the clinical challenges of emergent t |
Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare ConferenceNuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 11:15 a.m. ET. |
Nuvalent (NASDAQ:NUVL) Stock Price Down 2.5%Nuvalent Inc (NASDAQ:NUVL)’s share price was down 2.5% during trading on Tuesday . The stock traded as low as $19.06 and last traded at $19.06. Approximately 613 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 98,252 shares. The stock had previously closed at $19.54. Separately, Zacks Investment […] |
NUVL Price Returns
| 1-mo | -16.39% |
| 3-mo | -39.14% |
| 6-mo | -54.53% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -50.42% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...